Trials / Not Yet Recruiting
Not Yet RecruitingNCT07463521
A Study to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Ocular Myasthenia Gravis
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Ocular Myasthenia Gravis
- Status
- Not Yet Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 120 (estimated)
- Sponsor
- UCB Biopharma SRL · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to demonstrate the efficacy, safety and tolerability of rozanolixizumab compared with placebo in the treatment of adult study participants with Ocular Myasthenia Gravis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Rozanolixizumab | Rozanolixizumab will be administered by subcutaneous infusion. |
| DRUG | Placebo | Placebo will be administered by subcutaneous infusion. |
Timeline
- Start date
- 2026-05-29
- Primary completion
- 2028-12-01
- Completion
- 2029-01-22
- First posted
- 2026-03-11
- Last updated
- 2026-03-17
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07463521. Inclusion in this directory is not an endorsement.